SLNCF — Silence Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $291.43m
- $280.16m
- $0.56m
Annual cashflow statement for Silence Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | R2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | 10-K | 10-K | 10-K | 10-K |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Net Income/Starting Line | -63.1 | -50.3 | -54.2 | -45.3 | -88.6 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 12.3 | 12.1 | 19.4 | 10.1 | 15.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 59.5 | -19.4 | -15.2 | -33 | 10.2 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 9.36 | -57 | -49.5 | -67.6 | -62.3 |
| Capital Expenditures | -1.83 | -0.545 | -0.056 | -0.211 | -0.055 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 13.8 | -20 | 19.4 | -21.8 | -47.9 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 11.9 | -20.5 | 19.3 | -22 | -48 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 42.2 | 52.6 | 31.9 | 142 | 0.015 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 63.4 | -33.1 | 2.52 | 52.5 | -110 |